SH
Shalby Ltd (SHALBY)
₹122.15
Mkt cap
₹1,340 Cr
P/E ratio
34.20
P/B
1.29
Div yield
0.00%
ROE
2.45%
ROCE
6.12%
EPS (TTM)
₹3.57
Book value
₹95
52W range
111–228
Sector
Healthcare
Price history
Previous close
Shalby Ltd is engaged in healthcare delivery space in India. It operates a chain of multi-specialty hospitals across India. The business of the company is to offer tertiary and quaternary healthcare services to patients in various areas of specialization such as orthopaedics, complex joint replacements, cardiology, neurology, oncology, renal transplantations, etc. [1] The company is the global leader in knee replacement surgery and one of the top Indian hospitals in joint replacement surgery.
NSE SHALBYBSE 540797
Health check
Cautious
ValuationCheap
ProfitabilityWeak
GrowthModerate
TechnicalsBearish
52-week range
−46.35% from high₹122
₹111+10.43% from low₹228
Current
₹122.15
Prev close
₹121.89
Day
+0.21%
Price performance
1D
−0.52%
1W
−2.26%
1M
+5.27%
3M
−21.55%
6M
−28.88%
1Y
−46.07%
YTD
−39.79%
Financials
Revenue, profit & margin
P/E ratio
34.2×
SHALBY is 30% below the sector median of 49.2×
SHALBY34.2×
Sector median49.2×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 237.98 | 216.05 | 244.23 | 278.89 | 267.54 | 275.63 | 264.89 | 296.43 | 285.43 | 272.13 | 287.45 | 331.22 | 313.17 | |
| YoY Sales growth | +17.93% | +6.71% | +22.74% | +18.43% | +12.42% | +27.58% | +8.46% | +6.29% | +6.69% | -1.27% | +8.52% | +11.74% | +9.72% | |
| Expenses | 185.26 | 173.73 | 205.37 | 233.68 | 234.89 | 241.72 | 244.05 | 254.90 | 243.82 | 241.88 | 258.10 | 289.62 | 271.77 | |
| Operating Profit | 52.72 | 42.32 | 38.86 | 45.21 | 32.65 | 33.91 | 20.84 | 41.53 | 41.61 | 30.25 | 29.35 | 41.60 | 41.40 | |
| OPM % | 22.15% | 19.59% | 15.91% | 16.21% | 12.20% | 12.30% | 7.87% | 14.01% | 14.58% | 11.12% | 10.21% | 12.56% | 13.22% | |
| Other Income | 5.38 | 4.52 | 4.99 | 9.70 | 7.16 | 5.42 | 5.32 | 7.01 | 4.48 | 7.23 | 8.08 | 7.41 | 5.04 | |
| Interest | 3.17 | 3.63 | 6.47 | 8.12 | 9.26 | 10.66 | 10.67 | 9.37 | 9.65 | 10.64 | 9.34 | 10.57 | 11.05 | |
| Depreciation | 12.30 | 12.40 | 15.60 | 16.37 | 16.84 | 16.32 | 16.23 | 16.52 | 17.37 | 17.61 | 18.49 | 18.74 | 18.92 | |
| Profit before tax | 42.63 | 30.81 | 21.78 | 30.42 | 13.71 | 12.35 | -0.74 | 22.65 | 19.07 | 9.23 | 9.60 | 19.70 | 16.47 | |
| Tax % | 35.30% | 38.14% | 26.35% | 51.55% | 82.71% | 124.21% | 1,547.30% | 66.09% | 61.88% | 86.13% | -92.19% | 46.70% | 52.16% | |
| Net Profit | 27.57 | 19.06 | 16.04 | 14.74 | 2.36 | -2.99 | -12.19 | 7.68 | 7.28 | 1.28 | 18.46 | 10.50 | 7.89 | |
| EPS in Rs | 2.55 | 1.77 | 1.54 | 1.45 | 0.31 | -0.17 | -1.02 | 0.83 | 0.78 | 0.16 | 1.70 | 1.00 | 0.77 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202674.33%Promoter
Promoters74.33%
FIIs4.65%0.18
DIIs0.31%0.01
Public20.08%0.18
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Apollo Hospitals | ₹8,526.00 | 54.15 | 1,22,591 | 0.23% | 660 | +30.04% | 7,615 | +23.04% | 17.45% |
| Max Healthcare | ₹947.10 | 64.90 | 92,184 | 0.21% | 414 | −15.54% | 2,569 | +20.31% | 14.71% |
| Manipal Health | ₹681.40 | 95.57 | 89,630 | 0.00% | 285 | +10.29% | 3,399 | +37.32% | 12.10% |
| Aster DM Quality | ₹722.50 | 120.14 | 62,978 | 0.42% | 322 | +148.12% | 2,829 | +136.32% | 11.57% |
| Fortis Health. | ₹764.00 | 53.76 | 57,679 | 0.13% | 320 | +2.01% | 2,735 | +17.30% | 13.45% |
| Global Health | ₹1,454.00 | 60.38 | 39,095 | 0.03% | 219 | +51.38% | 1,469 | +33.64% | 17.37% |
| Narayana Hrudaya | ₹1,860.40 | 42.02 | 38,019 | 0.24% | 301 | +16.61% | 2,844 | +73.01% | 15.50% |
| Shalby | ₹124.06 | 34.17 | 1,340 | 0.00% | 8 | −1.31% | 313 | +9.72% | 6.12% |
| Median: 31 Co. | ₹535.00 | 49.15 | 7,179 | 0.00% | 40 | +22.67% | 431 | +22.77% | 14.62% |
Filings
Annual reports9
Concall transcripts79
PPTNov 2026RECNov 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptJun 2025PPTJun 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptJul 2024PPTJul 2024TranscriptJun 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Earnings Call Transcript 7 Nov - Earnings Call Transcript - conference call held on 04-Nov-2026Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Nov - Newspaper publication for Postal Ballot notice and remote e-votingDisclosure Under Regulation 30(5) Of SEBI(LODR) Regulations 4 Nov - Shalby revises Tushar Shah’s designation after his Executive Director appointment; no change in authorised personnel.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 4 Nov - Shalby shared the audio recording of its Q2 FY2027 earnings conference call.Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Nov





